CYCLOBENZAPRINE HYDROCHLORIDE Drug Interactions
Also known as: Cyclobenzaprine Hydrochloride
Cyclobenzaprine Hydrochloride is a muscle relaxant medication used to relieve muscle spasms caused by acute, painful muscle and bone conditions. It works by helping to relax the muscles, which can reduce pain, tenderness, and improve movement when used with rest and physical therapy. This medication is typically used for short periods to help you recover from these types of injuries.CYCLOBENZAPRINE HYDROCHLORIDE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience profound sedation, respiratory depression, hypotension, and psychomotor impairment. This can lead to increased risk of falls, accidental injury, coma, and potentially fatal respiratory arrest. The impairment of motor function and cognitive abilities can significantly impact daily activities and safety.
Mechanism
Buprenorphine, an opioid partial agonist, exerts its primary effects through mu-opioid receptor agonism, leading to central nervous system (CNS) depression. Cyclobenzaprine, a skeletal muscle relaxant, also causes significant CNS depression primarily through its action on the brainstem and its anticholinergic properties. The concomitant use of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe CNS and respiratory depression. If co-administration is unavoidable, reduce the starting dose of one or both drugs, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-pharmacological treatments or muscle relaxants with less sedating profiles if possible.
Patients may experience profound sedation, respiratory depression (ranging from hypoventilation to apnea), hypotension, and psychomotor impairment. This can lead to an increased risk of falls, accidental injury, and life-threatening respiratory compromise.
Mechanism
Fentanyl, an opioid analgesic, acts primarily on mu-opioid receptors in the central nervous system (CNS) to produce analgesia and respiratory depression. Cyclobenzaprine, a skeletal muscle relaxant, also exerts its effects through CNS depression, likely via its structural similarity to tricyclic antidepressants and its actions on brainstem centers. The co-administration of these agents results in additive CNS depressant effects.
Clinical Management
Avoid concomitant use of fentanyl and cyclobenzaprine if possible. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of respiratory depression and sedation, and educate them on the risks. Naloxone should be readily available for opioid-induced respiratory depression.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening.
Mechanism
Both oxycodone, an opioid analgesic, and cyclobenzaprine, a skeletal muscle relaxant, exert central nervous system (CNS) depressant effects. This interaction is due to their additive pharmacological actions on various neurotransmitter systems, leading to enhanced CNS depression.
Clinical Management
Concomitant use should generally be avoided. If unavoidable, initiate with lower doses of one or both drugs, monitor patients closely for signs of respiratory depression and excessive sedation, and advise patients against driving or operating heavy machinery. Consider alternative therapies if possible.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an elevated risk of respiratory depression, which can be life-threatening. Impaired motor coordination and cognitive function can also increase the risk of falls and accidents.
Mechanism
Both morphine, an opioid analgesic, and cyclobenzaprine, a centrally acting skeletal muscle relaxant, exert depressant effects on the central nervous system (CNS). This interaction is primarily pharmacodynamic, leading to an additive effect on GABAergic and other inhibitory neurotransmitter systems, resulting in enhanced CNS depression.
Clinical Management
Concomitant use should be avoided if possible. If co-administration is necessary, start with lower doses of one or both medications and monitor patients closely for signs of CNS depression, particularly respiratory depression and excessive sedation. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. There is an increased risk of respiratory depression, potentially leading to hypoventilation or apnea, and an elevated risk of falls and accidental injury.
Mechanism
Both tramadol and cyclobenzaprine exert central nervous system (CNS) depressant effects. Tramadol acts as a weak opioid agonist and also inhibits norepinephrine and serotonin reuptake, while cyclobenzaprine is a centrally acting skeletal muscle relaxant with anticholinergic properties. The co-administration leads to an additive pharmacological effect on CNS depression.
Clinical Management
Concomitant use should generally be avoided due to the significant risk of additive CNS depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and monitor patients closely for signs of respiratory depression, sedation, and mental status changes. Educate patients about the risks and advise against operating machinery or driving.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and syncope may also occur.
Mechanism
Codeine sulfate is an opioid analgesic that exerts its effects primarily through mu-opioid receptor agonism, leading to central nervous system (CNS) depression, including respiratory depression and sedation. Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants, which also causes significant CNS depression through its actions on the brainstem and spinal cord. The concomitant use of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use should generally be avoided due to the significant risk of additive CNS depression. If co-administration is unavoidable, initiate both medications at the lowest possible effective doses and monitor patients closely for signs of respiratory depression, excessive sedation, and altered mental status. Educate patients and caregivers about the risks and instruct them to seek immediate medical attention for symptoms such as difficulty breathing or extreme drowsiness.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effects include profound respiratory depression, which can be life-threatening, and hypotension. Impaired motor function and cognitive ability can also increase the risk of falls and accidents.
Mechanism
Methadone is a potent opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Cyclobenzaprine hydrochloride is a centrally acting skeletal muscle relaxant that also causes CNS depression, likely through its anticholinergic effects and action on the brainstem. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of methadone and cyclobenzaprine due to the significant risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, start with the lowest effective dose, and closely monitor patients for signs of respiratory depression, sedation, and hypotension. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression, coma, and even death. Other potential effects include dizziness, confusion, impaired psychomotor function, and hypotension. The risk is particularly elevated in elderly patients or those with pre-existing respiratory compromise.
Mechanism
Both hydromorphone, an opioid analgesic, and cyclobenzaprine, a centrally acting skeletal muscle relaxant, cause central nervous system (CNS) depression. When co-administered, their individual CNS depressant effects are additive, leading to an increased risk of severe adverse reactions. This additive effect primarily involves GABAergic potentiation and inhibition of neuronal excitability.
Clinical Management
Avoid concomitant use of hydromorphone and cyclobenzaprine if possible. If co-administration is necessary, use the lowest effective doses for the shortest duration possible, and closely monitor patients for signs of respiratory depression and sedation. Advise patients against operating heavy machinery or driving and educate them on the risks of CNS depression.
Patients may experience profound sedation, somnolence, dizziness, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening, along with hypotension and coma.
Mechanism
Both oxymorphone, an opioid agonist, and cyclobenzaprine, a centrally acting muscle relaxant with anticholinergic properties, cause central nervous system (CNS) depression. Their co-administration leads to an additive depressant effect on the brain and spinal cord, exacerbating sedation and respiratory depression.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate slowly. Closely monitor patients for signs of respiratory depression, excessive sedation, and altered mental status, especially during initiation or dose escalation. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, dizziness, confusion, and psychomotor impairment. There is an increased risk of respiratory depression, hypotension, and potentially life-threatening overdose symptoms. Impaired motor function can also increase the risk of falls and accidents.
Mechanism
Tapentadol is an opioid analgesic that acts as a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor, leading to central nervous system (CNS) depression. Cyclobenzaprine is a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants, which also causes significant CNS depression. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Concomitant use of tapentadol and cyclobenzaprine should generally be avoided due to the high risk of additive CNS depression. If co-administration is unavoidable, initiate both medications at the lowest effective doses and monitor patients closely for signs of sedation, respiratory depression, and cognitive impairment. Consider alternative non-opioid analgesics or non-pharmacological therapies for pain, and alternative muscle relaxants with less CNS depressant effects if appropriate.
For complete prescribing information:
View full CYCLOBENZAPRINE HYDROCHLORIDE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.